Chiome Bioscience’s Innovative Phase I Study on CBA-1535: A Potential Game-Changer in Cancer Treatment

Chiome Bioscience Inc. ((JP:4583)) announced an update on their ongoing clinical study.

Chiome Bioscience Inc. is conducting a Phase I clinical study titled ‘A Phase I Study to Assess the Safety, Tolerability and Biomarker Profiles of CBA-1535, Recombinant Protein Tribody in Patients With Previously Treated Advanced Solid Tumors.’ The study aims to evaluate the safety, tolerability, pharmacokinetics, biomarker profiles, and preliminary efficacy of CBA-1535 in patients with advanced solid tumors, marking a significant step in cancer treatment research.

The study tests the intervention CBA-1535, a recombinant protein tribody designed to engage T cells, either as a single agent or in combination with Pembrolizumab. This approach targets advanced solid tumors, aiming to improve patient outcomes.

This is a non-randomized, open-label, sequential study with no masking, focusing primarily on treatment. It involves two parts: dose-escalation of CBA-1535 alone and in combination with Pembrolizumab, to assess safety and efficacy.

The study began on April 7, 2025, with the latest update submitted on June 4, 2025. These dates are crucial as they indicate the study’s progression and ongoing recruitment status.

The study’s progress could positively influence Chiome Bioscience’s stock performance by attracting investor interest, particularly if preliminary results suggest potential efficacy. In the competitive oncology market, advancements in treatment options like CBA-1535 may enhance Chiome’s position.

The study is currently recruiting, with further details available on the ClinicalTrials portal.